Nestlé catches BioGaia bacillus


Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition products. BioGaia is receiving an upfront payment of a40m in the first quarter of 2012, and an additional a10.8m on achieving certain milestones in the next five years. Nestlé also has the option to extend the use of L. reuteri to other product areas. “Through the new agreement we have secured income that otherwise would not have been guaranteed under the original contract,” said Peter Rothschild, President of BioGaia. The Stockholm-based company announced it will use the proceeds to “further invest in its own brand” and for “a generous dividend policy”. A recent double-blind study in Indonesia showed that L. reuteri significantly reduced episodes of diarrhea. In the trial, 494 children received low lactose milk with or without L. reuteri or L. casei 431. The incidence of diarrhea episodes fell by 32% in the group supplemented with L. reuteri compared to placebo.
In the last few years, Nestlé has moved significantly into the field of functional food. In September 2010 it announced it would invest about US$500m in a new venture called Nestlé Health Science.



Stockholm – The Swedish Research Council is commissioning the Stockholm-based Karolinska Institute to host two new national infrastructures for research in biomedicine: the BioBanking and Molecular Resource Infrastructure of...



Personalised diagnostics open up possibilities for reducing adverse drug effects and choosing the most effective medicine for an individual patient based on a set of biomarkers. While many disease and stratification biomarkers...



Stockholm – Sweden’s Karolinska Institute medical university has received a grant of EUR10m (SEK 100m) from the Knut and Alice Wallenberg Foundation for a regenerative medicine research centre. It will be named the Wallenberg...



Stockholm – High levels of beta-tocopherol (vitamin E) in the blood appears to protect against the onset of Alzheimer's disease (AD) in advanced age, researchers at Sweden's Karolinska Institute have found out following a 6 year...



Uppsala - Swedish Orexo AB has licensed out its OX-CLI and OX-ESI programmes to Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV ("OMJ"). In addition to the programmes focusing on discovering and developing...



Huddinge – Pharmaceutical company Medivir AB, which focuses on drugs to fight infectious diseases caused by viruses, plans to raise EUR34m (SEK 325m) through the sale of 5.2 million shares at SEK62 in a rights offering taking...



Kund – Swedish company CellaVision AB plans to apply for a listing on the NASDAQ OMX Stockholm, Small Cap during the first half of 2010. The company wants to increase opportunities for institutional investors and create better...



Stockholm – The newly formed Swedish Orphan Biovitrum is ready to get down to business. To finance the acquisition of Swedish Orphan International, the best-known of Sweden’s biotech companies, Bio­vitrum AB, raised SEK1.5bn...

Displaying results 31 to 40 out of 182

< Previous 31-40 Next >

© 2007-2015 BIOCOM



All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015

Current issue

All issues